Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy

Hettihewa, L. M.; Jayasinghe, S. S.; Imendra, K. G.; Weerarathna, T. P.
January 2008
International Journal of Diabetes in Developing Countries;Jan-Mar2008, Vol. 28 Issue 1, p26
Academic Journal
journal article
Objective: To examine effects of pioglitazone (PIO) on systolic, diastolic, pulse and mean blood pressures (SBP, DBP, PP and MP, respectively) in type 2 diabetes mellitus (T2DM).Materials and Methods: One hundred and six normotensive patients with T2DM with mean fasting blood glucose (FBS; 183 +/- 6 mg/dl) were randomly divided into two groups. Test group was treated with 15 mg of PIO in addition to metformin 500 mg three times per day in both groups. SBP, DBP, PP and MP and fasting insulin, FBS and lipid profiles were measured before and after PIO therapy.Results: There was a significant reduction in SBP (123 +/- 2 vs. 118 +/- 2 mmHg, P < 0.05), PP (41 +/- 1 vs. 37 +/- 1 mmHg, P < 0.05), and MP (95 +/- 1 vs. 91 +/- 1, P < 0.05). Clinical reduction in DBP was observed but not significant (82 +/- 2 vs. 81 +/- 1 mmHg, P > 0.05). There was a significant correlation between decline in SBP and DBP with respective baseline values (r = 0.76, P < 0.001 and r = 0.62, P < 0.001, respectively). Changes in PP and MP strongly correlated with baseline values (r = 0.51, P < 0.05 and r = 0.56, P < 0.05, respectively). There was a parallel reduction of FBS (183 +/- 2 vs. 121 +/- 3, P < 0.001) but reduction in IR or lipid profiles was not significant in test group. Changes in BP were not significant in control group ( P > 0.05).Conclusion: PIO treatment of T2DM showed early reduction of SBP and MP within first 4 weeks. Results suggest that pharmacodynamic effects of PIO mainly affect the systolic component. We hereby suggest that reduction of BP by PIO is independent from mechanisms of changes in IR and dyslipidaemia in normotensive diabetic patients.


Related Articles

  • The Relation of Diabetes, Impaired Fasting Blood Glucose, and Insulin Resistance to Left Ventricular Structure and Function in African Americans. FOX, ERVIN R.; SARPONG, DANIEL F.; COOK, JOE C.; SAMDARSHI, TANDAW E.; NAGARAJARAO, HARSHA S.; LIEBSON, PHILIP R.; SIMS, MARIO; HOWARD, GEORGE; GARRISON, ROBERT; TAYLOR JR., HERMAN A. // Diabetes Care;Feb2011, Vol. 34 Issue 2, p507 

    OBJECTIVE--We assessed the relation of diabetes and insulin resistance (IR) on left ventricular (LV) structure and function in African Americans. RESEARCH DESIGN AND METHODS--Among those receiving echocardiograms in cycle 1 of the Jackson Heart Study, we assessed the sex-specific relation of...

  • Commentary: Sub-types of diabetes—what’s new and what’s not. Wild, Sarah H; Byrne, Christopher D // International Journal of Epidemiology;Dec2013, Vol. 42 Issue 6, p1600 

    No abstract available.

  • Renoprotective Effect of Metformin. Ahmadi, Farrokhlagha; Mohebi-Nejad, Azin // Iranian Journal of Kidney Diseases;Nov2013, Vol. 7 Issue 6, p417 

    The authors discuss the benefits and renoprotective effect of metformin for glycemic control and cardiovascular complications in diabetic patients. They explore studies that reveal the effect of metformin in gentamicin nephtotoxicity and reactive oxygen species (ROS). The authors agree that...

  • Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY.  // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1749 

    OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates...

  • Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. Lund, Søren Søgaard; Tarnow, Lise; Astrup, Anne Sofie; Hovind, Peter; Jacobsen, Peter Karl; Alibegovic, Amra Ciric; Parving, Ida; Pietraszek, Lotte; Frandsen, Merete; Rossing, Peter; Parving, Hans-Henrik; Vaag, Allan Arthur // PLoS Clinical Trials;Oct2008, Vol. 5 Issue 10, Special section p1 

    Background: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type- 2 diabetes. We investigated the effect of a one-year treatment...

  • Short Insulin Tolerance Test May Determine Thiazolidinediones Treatment in Type 2 Diabetes. Lee, Mi Y.; Koh, Jang H.; Jung, Pil M.; Shim, Myoung S.; Kim, Mi J.; Shin, Jang Y.; Shin, Young G.; Chung, Choon H. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA578 

    The short insulin tolerance test is a simple and reliable method of estimating insulin sensitivity. This study was designed to compare the insulin sensitizing effects of thiazolidinediones (TZDs) on the degree of insulin resistance determined by short insulin tolerance test, Kitt in type 2...

  • Effects of metformin on endothelial function in type 2 diabetes. SONGLIN WU; XIAOYAN LI; HONGMING ZHANG // Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 5, p1349 

    The aim of the present study was to examine the effect of metformin on endothelial function in patients with type 2 diabetes mellitus (T2DM). In total, 93 patients with T2DM and dissatisfactory glycemic control were randomly assigned to the metformin and pioglitazone groups and changes in...

  • Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content. Ravikumar, Balasubramanian; Gerrard, Jean; Man, Chiara Dalla; Firbank, Michael J.; Lane, Annette; English, Philip T.; Cobelli, Claudio; Taylor, Roy // Diabetes;Sep2008, Vol. 57 Issue 9, p2288 

    OBJECTIVE--Hepatic triglyceride is closely associated with hepatic insulin resistance and is known to be decreased by thiazolididinediones. We studied the effect of pioglitazone on hepatic triglyceride content and the consequent effect on postprandial endogenous glucose production (EGP) in type...

  • Potential Roles of Stevia rebaudiana Bertoni in Abrogating Insulin Resistance and Diabetes: A Review. Mohd-Radzman, Nabilatul Hani; Ismail, W. I. W.; Adam, Zainah; Jaapar, Siti Safura; Adam, Aishah // Evidence-based Complementary & Alternative Medicine (eCAM);2013, Vol. 2013, p1 

    Insulin resistance is a key factor in metabolic disorders like hyperglycemia and hyperinsulinemia, which are promoted by obesity and may later lead to Type II diabetes mellitus. In recent years, researchers have identified links between insulin resistance and many noncommunicable illnesses other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics